NAT2 and cancer: Based on our data on lower frequencies of the “slow” NAT2*5 variant in Nenets, compared with Europeans, we can assume that at the population level these northern peoples, unlike the studied European populations, are at a lower risk of developing cancer and other multifactorial diseases with which a polymorphic variant of NAT2*5 is associated.